PHATHOM PHARMACEUTICALS, INC. Shareholders' Equity
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Shareholders' Equity of -$344.27 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent -$344.27M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$336.95M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$438.17M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$422.53M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$344.27M 10-Q · filed 2026-07-30 |
| 2026-03-31 | -$336.95M 10-Q · filed 2026-07-30 |
| 2025-12-31 | -$438.17M 10-Q · filed 2026-07-30 |
| 2025-09-30 | -$422.53M 10-Q · filed 2025-10-30 |
| 2025-06-30 | -$405.83M 10-Q · filed 2026-07-30 |
| 2025-03-31 | -$338.38M 10-Q · filed 2026-07-30 |
| 2024-12-31 | -$253.58M 10-Q · filed 2026-07-30 |
| 2024-09-30 | -$187.11M 10-Q · filed 2025-10-30 |
| 2024-06-30 | -$233.83M 10-Q · filed 2025-10-30 |
| 2024-03-31 | -$148.50M 10-Q · filed 2025-10-30 |
| 2023-12-31 | -$72.76M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$17.77M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $17.60M 10-Q · filed 2024-11-07 |
| 2023-03-31 | -$90.19M 10-Q · filed 2024-11-07 |
| 2022-12-31 | -$74.81M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$26.42M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$7.00M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $38.03M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $72.16M 10-K/A · filed 2024-06-14 |
| 2021-09-30 | $103.48M 10-Q/A · filed 2022-11-09 |
| 2021-06-30 | $132.13M 10-Q/A · filed 2022-11-09 |
| 2021-03-31 | $164.34M 10-Q/A · filed 2022-11-09 |
| 2020-12-31 | $194.27M 10-K · filed 2023-02-28 |
| 2020-09-30 | $156.39M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $188.42M 10-Q · filed 2021-11-08 |
| 2020-03-31 | $208.69M 10-Q · filed 2021-11-08 |
| 2019-12-31 | $227.96M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$152.46M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$84.39M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$2.54M 10-Q · filed 2020-11-10 |
| 2018-12-31 | -$1.29M 10-K · filed 2021-03-30 |
| 2018-09-30 | -$802.00K 10-Q · filed 2019-11-25 |
| 2018-06-30 | -$512.00K 10-Q · filed 2019-11-25 |
| 2018-03-31 | -$252.00K 10-Q · filed 2019-11-25 |
| 2017-12-31 | $0.00 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |